Pharmaceutical formulation comprising cineole and amoxicillin

Abstract

The present invention relates to a pharmaceutical formulation in powder form comprising amoxicillin, cineole and a pharmaceutically acceptable oil. The present formulation may also comprise clavulanic acid. It is intended for oral administration, preferably after suspension in an aqueous solvent. The present invention also relates to a combination of cineole and amoxicillin for use in the treatment of an infectious pathology, preferably a bacterial infection, in an individual. The present combination may also comprise a β-lactamase inhibitor, preferably clavulanic acid. The combination according to the invention makes it possible in particular to combat infections caused by bacteria that are resistant to antibiotics, preferably to antibiotics of the β-lactamine family.

1 . A molecular complex comprising at least three amoxicillin molecules organized linearly or in a ring and interacting with each other by non-covalent bonds. 
     
     
         2 . The molecular complex of  claim 1 , wherein said complex is formed from three to six amoxicillin molecules. 
     
     
         3 . The molecular complex of  claim 1 , wherein said molecular complex is formed from three or four amoxicillin molecules. 
     
     
         4 . The molecular complex of  claim 1 , wherein said molecular complex is formed of four amoxicillin molecules. 
     
     
         5 . The molecular complex of  claim 1 , wherein the amoxicillin molecules are organized in a ring. 
     
     
         6 . The molecular complex of  claim 1 , wherein the amoxicillin molecules are organized linearly. 
     
     
         7 . The molecular complex of  claim 1 , which is obtained or obtainable by placing amoxicillin in solution in the presence of cineole in an aqueous solvent and in the absence of detergent. 
     
     
         8 . The molecular complex of  claim 7 , which is obtained or obtainable by placing amoxicillin in solution in the presence of cineol with a mass ratio of amoxicillin to cineol of between about 0.01 and about 1000. 
     
     
         9 . The molecular complex of  claim 8 , wherein the mass ratio of amoxicillin to cineol is between about 0.1 and about 100. 
     
     
         10 . The molecular complex of  claim 8 , wherein the mass ratio of amoxicillin to cineol is between about 1 and about 10. 
     
     
         11 . The molecular complex of  claim 8 , wherein the mass ratio of amoxicillin to cineol is about 5. 
     
     
         12 . A pharmaceutical composition comprising the molecular complex according to  claim 1 . 
     
     
         13 . A method of treating an infectious pathology in an individual comprising the administration of a molecular complex according to  claim 1  or a pharmaceutical composition comprising said molecular complex to said individual. 
     
     
         14 . The method of  claim 13 , wherein said pathology is an infectious pathology of bacterial origin. 
     
     
         15 . The method of  claim 13 , wherein said infectious pathology is a bacterial infection selected from the group consisting of cystitis, recurring acute cystitis, bacterial sinusitis, acute maxillary sinusitis, otitis, acute otitis media, bronchitis, chronic and/or acute bronchitis, bronchopneumopathy, chronic and/or acute bronchopneumopathy, pyelonephritis, upper genital tract infections, parodontitis, severe stomatological infections, abscesses, phlegmons, cellulites, animal bites, bone and joint infections, and osteomyelitis.